Artículos relacionados
Área salud
[Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review
marzo 18, 2024
Área salud, Actas Dermo-Sifiliográficas, Elsevier España, Medicina, Vol. 115. Núm. 3. (Marzo 2024)
Oral roflumilast is a phosphodiesterase-4 inhibitor approved for the prevention of exacerbations of chronic obstructive pulmonary disease and chronic bronchitis. In dermatology, topical roflumilast is authorized by the US Food and Drug Administration for the […]
